{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-082314","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.037774+00:00","generated_at":"2026-06-17T13:33:23.991683+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Biomea Fusion reports 89% response rate and 1% median HbA1c reduction at 4 weeks for BMF-219 in T2DM Phase II","bullets":["Cohort 3 (100 mg BMF-219 without food, n=9) showed 89% response rate, median HbA1c reduction of -1.0% at day 28.","56% of Cohort 3 patients achieved >=1.0% HbA1c reduction; placebo (n=4) had median reduction of -0.1% to -0.15%.","BMF-219 was well-tolerated; no discontinuations, serious AEs, or severe AEs across healthy volunteers and T2DM cohorts.","Company plans to explore additional dosing periods >4 weeks and potential utility in type 1 diabetes.","Dose escalation continues; negative food effect observed (3-fold exposure difference between fed and fasted cohorts)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-082314","json":"https://secwatch.observer/filing/0001193125-23-082314.json","markdown":"https://secwatch.observer/filing/0001193125-23-082314.md","text":"https://secwatch.observer/filing/0001193125-23-082314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312523082314/0001193125-23-082314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312523082314/d311150d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:33:23.991683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}